Literature DB >> 2836880

Forecasting the personal medical care costs of AIDS from 1988 through 1991.

F J Hellinger1.   

Abstract

The personal medical care costs of those diagnosed with acquired immunodeficiency syndrome (AIDS) in 1988 are forecast to be $2.2 billion, an amount that will increase to $4.5 billion in 1991. This is the first study to include the cost of purchasing azidothymidine (AZT), also called zidovudine, a palliative treatment for AIDS. The forecasts of this study are lower than those reported by Rice and Scitovsky, and other researchers, because the data are more recent and AIDS patients are receiving more care on an outpatient basis and staying in the hospital fewer days. They are also lower because projections for the number of AIDS cases diagnosed in future years are lower than those made by the Centers for Disease Control (CDC). This study projects that about 38,000 AIDS cases will be diagnosed in 1988 and 73,000 in 1991. The projections in this study are derived using data on the number of AIDS cases reported to CDC from January 1984 to October 1987, while the CDC projections employed by Rice and Scitovsky were derived using data from June 1981 to May 1986. It is also projected that the lifetime cost of treating an AIDS patient will increase from $57,000 in 1988 to $61,800 in 1991 due to the wider use of AZT.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2836880      PMCID: PMC1478076     

Source DB:  PubMed          Journal:  Public Health Rep        ISSN: 0033-3549            Impact factor:   2.792


  9 in total

1.  Acquired immunodeficiency syndrome: current and future trends.

Authors:  W M Morgan; J W Curran
Journal:  Public Health Rep       Date:  1986 Sep-Oct       Impact factor: 2.792

2.  Review of death certificates to assess completeness of AIDS case reporting.

Authors:  A M Hardy; E T Starcher; W M Morgan; J Druker; A Kristal; J M Day; C Kelly; E Ewing; J W Curran
Journal:  Public Health Rep       Date:  1987 Jul-Aug       Impact factor: 2.792

3.  AIDS: German survey's gloomy outlook.

Authors:  B Johnstone
Journal:  Nature       Date:  1986 Nov 20-26       Impact factor: 49.962

4.  The economic impact of the first 10,000 cases of acquired immunodeficiency syndrome in the United States.

Authors:  A M Hardy; K Rauch; D Echenberg; W M Morgan; J W Curran
Journal:  JAMA       Date:  1986-01-10       Impact factor: 56.272

5.  Transmission dynamics of HIV infection.

Authors:  R M May; R M Anderson
Journal:  Nature       Date:  1987 Mar 12-18       Impact factor: 49.962

6.  Medical care costs of patients with AIDS in San Francisco.

Authors:  A A Scitovsky; M Cline; P R Lee
Journal:  JAMA       Date:  1986-12-12       Impact factor: 56.272

7.  The provision and financing of medical care for AIDS patients in US public and private teaching hospitals.

Authors:  D P Andrulis; V S Beers; J D Bentley; L S Gage
Journal:  JAMA       Date:  1987-09-11       Impact factor: 56.272

8.  The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial.

Authors:  M A Fischl; D D Richman; M H Grieco; M S Gottlieb; P A Volberding; O L Laskin; J M Leedom; J E Groopman; D Mildvan; R T Schooley
Journal:  N Engl J Med       Date:  1987-07-23       Impact factor: 91.245

9.  Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City.

Authors:  R Rothenberg; M Woelfel; R Stoneburner; J Milberg; R Parker; B Truman
Journal:  N Engl J Med       Date:  1987-11-19       Impact factor: 91.245

  9 in total
  10 in total

1.  Administrative challenges to working with HIV-positive clients: experiences of mental health and substance abuse program directors in Florida.

Authors:  M G Dow; M D Knox; D A Cotton
Journal:  J Ment Health Adm       Date:  1989

2.  Updated forecasts of the costs of medical care for persons with AIDS, 1989-93.

Authors:  F J Hellinger
Journal:  Public Health Rep       Date:  1990 Jan-Feb       Impact factor: 2.792

Review 3.  Zidovudine: a review of pharmacoeconomic and quality-of-life considerations for its use in patients with human immunodeficiency virus.

Authors:  H D Langtry; K J Palmer; P Benfield
Journal:  Pharmacoeconomics       Date:  1993-04       Impact factor: 4.981

4.  Assessing the economic impact of AIDS in local communities. Current and projected costs for San Diego County.

Authors:  R L Seidman; S J Williams; L M Mortensen
Journal:  West J Med       Date:  1989-10

5.  Analysis of Michigan Medicaid costs to treat HIV infection.

Authors:  D J Solomon; A J Hogan; R R Bouknight; C T Solomon
Journal:  Public Health Rep       Date:  1989 Sep-Oct       Impact factor: 2.792

6.  Planning community-wide services for persons with HIV infection in an area of moderate incidence.

Authors:  S L Lenker; D P Lubeck; A Vosler
Journal:  Public Health Rep       Date:  1993 May-Jun       Impact factor: 2.792

7.  Effect of changing patterns of care and duration of survival on the cost of treating the acquired immunodeficiency syndrome (AIDS).

Authors:  G R Seage; S Landers; G A Lamb; A M Epstein
Journal:  Am J Public Health       Date:  1990-07       Impact factor: 9.308

8.  The impact of HIV-related illness on employment.

Authors:  E H Yelin; R M Greenblatt; H Hollander; J R McMaster
Journal:  Am J Public Health       Date:  1991-01       Impact factor: 9.308

9.  The invisible women: caregiving and the construction of AIDS health services.

Authors:  N G Schiller
Journal:  Cult Med Psychiatry       Date:  1993-12

10.  Florida's Medicaid AIDS waiver: an assessment of dimensions of quality.

Authors:  M E Cowart; J M Mitchell
Journal:  Health Care Financ Rev       Date:  1995
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.